Articles with public access mandates - Sergio GiraltLearn more
Not available anywhere: 15
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102 …
A Krishnan, MC Pasquini, B Logan, EA Stadtmauer, DH Vesole, E Alyea, ...
The lancet oncology 12 (13), 1195-1203, 2011
Mandates: US National Institutes of Health
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ...
Leukemia 35 (1), 18-30, 2021
Mandates: US National Institutes of Health
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
B Diamond, N Korde, AM Lesokhin, EL Smith, U Shah, S Mailankody, ...
The Lancet Haematology 8 (6), e422-e432, 2021
Mandates: US National Institutes of Health
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation
D Zamarin, S Giralt, H Landau, N Lendvai, A Lesokhin, D Chung, ...
Bone marrow transplantation 48 (3), 419-424, 2013
Mandates: US National Institutes of Health
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance
D Zamarin, SM Devlin, ME Arcila, H Landau, A Lesokhin, N Lendvai, ...
Leukemia 27 (12), 2422-2424, 2013
Mandates: US National Institutes of Health
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
R Champlin, M de Lima, P Kebriaei, G Rondon, T Fisher, E Jabbour, ...
Clinical Lymphoma and Myeloma 9, S261-S265, 2009
Mandates: US National Institutes of Health
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?
S Giralt, G Koehne
Current hematologic malignancy reports 8, 284-290, 2013
Mandates: US National Institutes of Health
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia
P Anderlini, SA Acholonu, GJ Okoroji, RE Bassett Jr, EJ Shpall, ...
Leukemia & Lymphoma 52 (1), 137-141, 2011
Mandates: US National Institutes of Health
Treatment of transplant-eligible patients with multiple myeloma in 2014
H Landau, S Giralt
Hematology/Oncology Clinics 28 (5), 815-827, 2014
Mandates: US National Institutes of Health
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma
PB Dahi, CH Moskowitz, SA Giralt, HM Lazarus
Expert review of hematology 12 (4), 255-264, 2019
Mandates: US National Institutes of Health
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
PB Dahi, CH Moskowitz, SA Giralt, HM Lazarus
Expert review of hematology 12 (6), 407-418, 2019
Mandates: US National Institutes of Health
BK polyoma virus nephropathy in hematopoietic cell transplant recipients
YJ Lee, IG Glezerman, R Tamari, CS Sauter, SE Prockop, F Boulad, ...
Journal of Onco-Nephrology 3 (3), 113-123, 2019
Mandates: US National Institutes of Health
Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series
A Gomez-Arteaga, M Scordo, R Tamari, JD Ruiz, AA Jakubowski, ...
Bone Marrow Transplantation 55 (12), 2326-2330, 2020
Mandates: US National Institutes of Health
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
A D’Souza, R Brazauskas, BQ Teng, G Yun, H Uttley, J Dong, MB Dwinell, ...
Bone Marrow Transplantation 58 (3), 334-336, 2023
Mandates: US National Institutes of Health
Pattern of Reconstitution and Relapse Following Autologous Bone Marrow Transplantation for Chronic Myelogenous Leukemia
AB Deisseroth, J Hester, M Korbling, D Seong, R Champlin, H Kantarjian, ...
Autologous Stem Cell Transplantation, 65-71, 2020
Mandates: US National Institutes of Health
Available somewhere: 383
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
ML Davila, I Riviere, X Wang, S Bartido, J Park, K Curran, SS Chung, ...
Science translational medicine 6 (224), 224ra25-224ra25, 2014
Mandates: US National Institutes of Health
Defining the intensity of conditioning regimens: working definitions
A Bacigalupo, K Ballen, D Rizzo, S Giralt, H Lazarus, V Ho, J Apperley, ...
Biology of blood and marrow transplantation 15 (12), 1628-1633, 2009
Mandates: US National Institutes of Health
Lenalidomide after stem-cell transplantation for multiple myeloma
PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ...
New England Journal of Medicine 366 (19), 1770-1781, 2012
Mandates: US National Institutes of Health
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
Mandates: US National Institutes of Health
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
Y Taur, RR Jenq, MA Perales, ER Littmann, S Morjaria, L Ling, D No, ...
Blood, The Journal of the American Society of Hematology 124 (7), 1174-1182, 2014
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program